What was the primary driver of the significant increase in net income for the nine-month period?

The primary driver was the absence of a substantial impairment charge on equity securities (specifically, the investment in VillageMD) that was recorded in the same period last year. This year's results benefited from not having that charge.

How did the divestiture of the Medicare Advantage business affect the company's financial performance?

The divestiture of the Medicare Advantage business led to a decrease in Cigna Healthcare's revenues by 9% for the nine months ended September 30, 2025, compared to the prior year. This also impacted the Medical Care Ratio and SG&A expense ratio within that segment.

What is the outlook for the Evernorth Health Services segment?

The Evernorth Health Services segment continues to show strong growth, with adjusted revenues up 16% and pre-tax adjusted income from operations up 4% for the nine months ended September 30, 2025. This growth is attributed to increased pharmacy utilization, customer expansion, and contract affordability improvements. The company is also investing in new initiatives like a rebate-free model, which may impact short-term profitability but is expected to drive long-term value.

How is Cigna Group managing its debt and capital structure?

Cigna Group actively manages its capital structure. During the period, they issued $4.5 billion in new senior notes and repaid $2.0 billion of a term loan. They also repurchased $2.6 billion of common stock. The company maintains a substantial revolving credit facility and a commercial paper program for liquidity support, and it continues to prioritize capital deployment towards strategic investments, dividends, and share repurchases.

CI 10-Q Quarterly Report Q3 FY2025 — Revenue, Net Income, EPS

Summary

The Cigna Group reported a significant increase in net income for the nine months ended September 30, 2025, driven by the absence of a substantial prior-year investment impairment. Total revenues grew by 12% year-over-year, largely due to strong performance in Pharmacy revenues, which increased by 17%. This growth was primarily fueled by higher utilization and customer expansion within the Evernorth Health Services segment. However, the Cigna Healthcare segment experienced a revenue decline of 9%, largely attributable to the divestiture of its Medicare Advantage business. Despite this, the company managed its expenses effectively, with Selling, General, and Administrative (SG&A) expenses remaining relatively flat year-over-year when excluding the impact of strategic optimization programs. The company also strengthened its balance sheet by issuing new senior notes and repaying existing debt, demonstrating a proactive approach to capital management.

Financial Highlights

48 data points

Beta

Revenue

$69.75B

0.2% Gross Margin

Net Income

$1.87B

0.0% Net Margin

EPS (Diluted)

$6.98

Total Assets

$157.92B

Cash & Equivalents

$6.03B

Free Cash Flow

$3.42B

Financial Statements

Beta

Revenue	$69.75B
Cost of Revenue	$55.53B
Gross Profit	$14.22B
SG&A Expenses	$3.36B
Operating Income	$2.58B
Interest Expense	$363.00M
Net Income	$1.87B
EPS (Basic)	$7.02
EPS (Diluted)	$6.98
Shares Outstanding (Diluted)	267.53M

Key Highlights

1Total revenues increased by 12% to $202.4 billion for the nine months ended September 30, 2025, compared to the prior year, driven by strong growth in Pharmacy revenues.
2Shareholders' net income saw a substantial increase of 135% to $4.7 billion for the nine months ended September 30, 2025, largely due to the absence of a prior-year investment impairment.
3The divestiture of the Medicare Advantage business impacted Cigna Healthcare's revenues, which decreased by 9% year-over-year for the nine months ended September 30, 2025.
4Evernorth Health Services demonstrated robust growth, with adjusted revenues up 16% and pre-tax adjusted income from operations up 4% for the nine months ended September 30, 2025.
5The company successfully managed its debt, issuing $4.5 billion in new senior notes and repaying $2.0 billion under a term loan facility during the period.
6Selling, General, and Administrative (SG&A) expenses remained flat year-over-year for the nine months, reflecting effective cost management despite strategic investments.
7The company repurchased $2.6 billion of its common stock during the nine months ended September 30, 2025, continuing its capital return strategy.

Cigna Group Quarterly Report for Q3 Ended Sep 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions